10-K/A: American Oncology Network Files Amended 10-K Report, Addressing Proxy Statement Delay and Including Updated Certifications

American Oncology Network has filed an amendment to its annual report on Form 10-K to include required information and updated certifications due to a delay in filing its definitive proxy statement.

Summary

• American Oncology Network, Inc. filed an amendment to its annual report on Form 10-K to include information typically found in Part III of the form, which was delayed due to the company not filing its definitive proxy statement within 120 days of the fiscal year end.
• The amendment also includes new certifications from the company's principal executive officer and principal financial officer.
• The original filing was made on March 28, 2024, and this amendment does not update any disclosures to reflect events after that date.
• The company's Class A common stock and warrants are traded on the Nasdaq Stock Market LLC under the symbols AONC and AONCW respectively.
• As of April 16, 2024, the company had 12,430,936 shares of Class A common stock and 23,725,998 shares of Class B common stock outstanding.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, but the delay in the proxy statement and the need for an amendment slightly lowers the sentiment. The company appears to be operating within standard corporate governance practices.

Positives

• The company has a clawback policy in place to recover erroneously awarded incentive-based compensation.
• The company has a formal written policy for the review and approval of related party transactions.
• The company has a code of ethics that applies to all employees, officers, and directors.
• The company has an insider trading policy and a hedging policy.
• The company's audit committee has pre-approval policies for services provided by the independent auditor.

Negatives

• The company delayed filing its definitive proxy statement, necessitating this amendment to the 10-K report.
• The company did not have a non-employee director compensation program in 2023.

Risks

• The company's financial results could be subject to restatement, potentially triggering the clawback policy.
• The company's related party transactions could pose conflicts of interest if not properly managed.
• The company's compliance with legal and regulatory requirements is subject to ongoing review and oversight.
• The company's executive compensation program could be subject to scrutiny if not aligned with performance goals.
• The company's reliance on key personnel could pose a risk if they were to leave the company.

Future Outlook

The company expects to adopt a director compensation policy during the 2024 fiscal year.

Management Comments

• Todd Schonherz, CEO, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact.
• David Gould, CFO, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact.

Industry Context

This filing is typical for public companies that need to amend their annual reports due to delays in filing proxy statements. The company's focus on oncology services places it within the healthcare industry, which is subject to specific regulatory and compliance requirements.

Comparison to Industry Standards

• The company's executive compensation structure, including base salaries, bonuses, and benefits, is comparable to other healthcare companies of similar size and scope.
• The company's corporate governance practices, including the establishment of an audit committee, compensation committee, and nominating and corporate governance committee, are consistent with industry standards for publicly traded companies.
• The company's use of PricewaterhouseCoopers LLP as its independent registered public accounting firm is a common practice among publicly traded companies.
• The company's related party transaction policy is in line with best practices for corporate governance.

Management Changes

Stakeholder Impact

• Shareholders will receive updated information about the company's financial performance and corporate governance.
• Employees will be subject to the company's code of ethics and insider trading policy.
• The company's executive officers will be subject to the clawback policy.
• The company's directors will be subject to the company's corporate governance practices.

Next Steps

• The company will need to file its definitive proxy statement.
• The company expects to adopt a director compensation policy during the 2024 fiscal year.

Key Dates

Keywords

10-K, amendment, proxy statement, executive compensation, corporate governance, related party transactions, audit committee, financial reporting, Sarbanes-Oxley, Nasdaq, insider trading, clawback policy